Key result
Parkinson's disease patients exhibited significant cardiovascular autonomic impairment compared to healthy controls, including reduced SDNN (21.3 vs 32.5 ms) and increased systolic BP drop on tilt.
Why the study?
Despite its recognized impact on quality of life, comprehensive evaluation of cardiovascular autonomic dysfunction in Parkinson's disease remains limited.
Does dopaminergic therapy improve cardiovascular autonomic dysfunction in patients with Parkinson's disease?
Population
60 Parkinson's disease patients and 30 age- and sex-matched healthy controls
Comparison
Parkinson's disease patients vs healthy controls, and dopaminergic medication ON vs OFF states
Design
Cross-sectional study
Authors
Loading...
Should not yet change autonomic monitoring or dopaminergic use in PD; leaves open these parameters as disease-progression markers.
Cross-Sectional (n=90)
No
Does dopaminergic therapy improve cardiovascular autonomic dysfunction in patients with Parkinson's disease?
Absolute Event Rate: 21.3% vs 32.5%
p-value: p=<0.001
Parkinson's disease is associated with marked cardiovascular autonomic dysfunction that correlates with disease severity, and dopaminergic therapy provides modest improvements in these autonomic parameters.
Kumar et al. (2026) conducted a cross-sectional in Parkinson's disease (n=90). Parkinson's disease vs. Healthy controls was evaluated on Standard deviation of NN intervals (SDNN) (p=<0.001). Parkinson's disease patients exhibited significant cardiovascular autonomic impairment compared to healthy controls, including reduced SDNN (21.3 vs 32.5 ms) and increased systolic BP drop on tilt.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: